Skip to main content

Millennium Gobbles Up Predictive Medicine, Eyes Pharmacogenomics Future

Premium

C

AMBRIDGE, Mass.--Millennium Pharmaceuticals announced that it will acquire the remaining shares of its Millennium Predictive Medicine subsidiary that it does not already own, making it a wholly owned subsidiary. The company said that the transaction, a stock-for-stock exchange, will align more closely Millennium’s therapeutic and predictive medicine discovery and development efforts.

The predictive medicine company develops what it calls Diagnomic and pharmacogenomic products and services. Diagnomics are molecular diagnostics that describe a patient’s current medical condition and provide prognostic and therapeutic information. Pharmacogenomic tests determine a patient’s response to a specific therapeutic based on their genetic information.

Filed under

The Scan

Not Kept "Clean and Sanitary"

A Food and Drug Administration inspection uncovered problems with cross contamination at an Emergent BioSolutions facility, the Wall Street Journal reports.

Resumption Recommendation Expected

The Washington Post reports that US officials are expected to give the go-ahead to resume using Johnson & Johnson's SARS-CoV-2 vaccine.

Canada's New Budget on Science

Science writes that Canada's new budget includes funding for the life sciences, but not as much as hoped for investigator-driven research.

Nature Papers Examine Single-Cell, Multi-Omic SARS-CoV-2 Response; Flatfish Sequences; More

In Nature this week: single-cell, multi-omics analysis provides insight into COVID-19 pathogenesis, evolution of flatfish, and more.